Navigation Links
Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
Date:11/8/2012

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2012 Global Healthcare Conference in London on Thursday, November 15th at 1:40 p.m. GMT.

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

Contact: Ryan Maynard   
Phone: 650.624.1284   
Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Rigel Announces Third Quarter 2012 Financial Results
2. Rigel to Present at UBS Global Life Sciences Conference
3. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
4. Rigel Announces Second Quarter 2012 Financial Results
5. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
6. Rigel Announces First Quarter 2012 Financial Results
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
9. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
10. VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings
11. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , March 1, 2017  The Pharmaceutical Care ... Senate Finance Committee,s vote to advance the nomination of ... Medicare and Medicaid Services Administrator: "The ... bright spot in American health care. By offering an ... using cutting-edge, cost-saving tools like pharmacy networks and home ...
(Date:3/1/2017)... , March 1, 2017 The global  Intraoperative Neuromonitoring (IONM) ... new report by Grand View Research, Inc. The intraoperative neuromonitoring market is anticipated ... the hospitals adopting intraoperative monitoring in a wide spectrum of surgeries. ... ... Grand View Research Logo ...
(Date:2/28/2017)... Mechanical Ventilators Market: Scope of the Study ... This report provides forecast and analysis of the mechanical ... provides historical data of 2015 along with forecast from ... and volume (units). The report also includes macroeconomic indicators ... It includes drivers and restraints of the mechanical ventilators ...
Breaking Medicine Technology:
(Date:3/1/2017)... BEVERLY HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... invasive cryoablation for the treatment of early stage breast cancer and where it fits ... Screens, Genes & The Choices We Make .” The event brings together leading cancer ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living ... mobile app Time & Go. , Time & Go app is the ultimate strategic ... and well-being. Efficient time management methods enable people to work smarter, not harder, that's ...
(Date:3/1/2017)... , ... March 01, 2017 , ... March 2017 – ... months when people don’t want to stop training to brave the cold weather, snow ... treadmill to a small incline can help protect these vulnerable joints, says orthopaedic surgeon ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale ... the truth about his life and mysterious disappearance. “McFarnia” is the creation of published ... in North Carolina. He currently serves as a Chaplain with Transport for Christ at ...
(Date:3/1/2017)... ... March 01, 2017 , ... “Letter of Love”: a ... author, Maria Teresa Hamilton, survivor of the Civil War in El Salvador, wife, mother, ... the age of fifteen. I dedicated myself to serve in very poor communities, and ...
Breaking Medicine News(10 mins):